How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...

Van ECK Associates Corp reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.5% in the 3rd quarter, according to the company in its most recent 13F filing with the ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

Halozyme Therapeutics Inc (HALO) reports a 34% revenue increase, raises full-year guidance, and expands partnerships despite ...

JMP Securities analyst Jason Butler has reiterated their bullish stance on HALO stock, giving a Buy rating yesterday. Jason Butler has given ...

Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.

In a report released yesterday, Brendan Smith from TD Cowen maintained a Buy rating on Halozyme (HALO – Research Report), with a price ...

Today, we revisit Halozyme Therapeutics for the first time since late spring as the stock has pulled back some 20% from recent all-time highs. Halozyme's ENHANZE platform enhances drug delivery ...

Short interest in Halozyme Therapeutics Inc (NASDAQ:HALO) increased during the last reporting period, rising from 9.64M to 9.85M. This put 10.54% of the company's publicly available shares short.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...